Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ · Healthcare
Regeneron Pharmaceuticals, Inc. Net Income 2008–2025
Regeneron Pharmaceuticals, Inc. annual/quarterly net income history and growth rate from 2008 to 2026. Net income is the total earnings of a company after all expenses, including taxes and interest, have been deducted from total revenues.
- Regeneron Pharmaceuticals, Inc. net income for the quarter ending March 31, 2026 was 727.2 M, a 10.08% decrease year-over-year.
- Regeneron Pharmaceuticals, Inc. net income for the twelve months ending March 31, 2026 was 4.4 B, a 2.56% decrease year-over-year.
- Regeneron Pharmaceuticals, Inc. annual net income for 2025 was 4.5 B, a 2.09% increase from 2024.
- Regeneron Pharmaceuticals, Inc. annual net income for 2024 was 4.4 B, a 11.61% increase from 2023.
- Regeneron Pharmaceuticals, Inc. annual net income for 2023 was 4.0 B, a 8.87% decrease from 2022.
- Regeneron Pharmaceuticals, Inc. annual net income for 2022 was 4.3 B.
Net Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Regeneron Pharmaceuticals Inc. Net Income — FAQ
Regeneron Pharmaceuticals Inc. (REGN) net income over the last 18 years — annual and quarterly figures with year-over-year growth and charts.
What is Regeneron Pharmaceuticals Inc.'s net income?
Regeneron Pharmaceuticals Inc. (REGN) reported net income of $4.50B for fiscal 2025.
Where can I see REGN's net income history?
The chart and table above show Regeneron Pharmaceuticals Inc.'s net income by year and by quarter, including the growth rate.